CT1 is a carbohydrate moiety of CD45 that is expressed on fetal thymocytes in vivo. Examination of CT1 expression on thymocyte subsets revealed that primarily pro-T cells (CD44 ⍣ CD25 ⍣ ) and pre-T cells (CD44 -CD25 ⍣ ) expressed CT1. Interestingly, non-T-lineage committed lymphoid progenitors (CD44 ⍣ CD25 -) lacked CT1 indicating temporal regulation of expression of this determinant in early T-lineage committed development. In addition, CT1 was expressed by the majority of thymocytes in RAG-2 -/-mice where thymocyte development is blocked at the CD44 -CD25 ⍣ stage. Since late pre-T cells (CD44 -CD25 -) lacked the CT1 epitope we tested whether pre-TCR triggering regulated CT1 expression. Injection of CD3ε-specific mAb into RAG-2 -/-mice induces differentiation of immature thymocytes to the double-positive stage of thymocyte development. Using this system, we demonstrated that expression of CT1 by RAG-2 -/-thymocytes was rapidly lost from pre-T cells following anti-CD3 mAb treatment. Furthermore, the decline in CT1 expression induced by CD3 signaling paralleled a loss of mRNA for the glycosyltransferase responsible for the addition of CT1 to CD45. Flow cytometric analysis also revealed that the loss of the CT1 epitope was inversely correlated with an increase in peanut agglutinin ligand expression, demonstrating a complex regulation of cell surface glycosylation at a critical juncture in thymocyte development.
Introduction
The process by which mature T cells are generated in the thymus is well-regulated with discrete checkpoints to insure that only useful T cells that recognize self-MHC with foreign antigen survive the process (1, 2) . In mice rendered deficient in the genes necessary for TCR gene rearrangement, the thymus is small and contains only immature lymphoid progenitors (3-5). Flow cytometric analysis has shown that recombination activating gene-2 (Rag-2)-deficient thymocytes are blocked at the CD3 -CD4 -CD8 -(commonly called triple negative or TN) stage of development (5) . Four subsets of TN thymocytes have been defined by their expression of CD44 and CD25 (6) . Fetal thymus organ culture and in vivo transfer experiments have demonstrated that the progression of thymocyte maturation is from CD44 ϩ CD25 -(non-T committed progenitors) → CD44 ϩ CD25 ϩ (pro-T) → CD44 -CD25 ϩ (early pre-T) → CD44 -CD25 -(late pre-T) (7) . Thymocytes from mice deficient in Rag-1 or Rag-2 are blocked at the CD44 -CD25 ϩ stage (4, 5) .
Experiments utilizing Rag-2-deficient mice expressing a
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Transmitting editor: M. J. Bevan Received 13 October 1997, accepted 22 December 1997 transgenic rearranged TCRβ chain demonstrate that cell surface expression of a TCRβ chain on immature thymocytes is sufficient to remove the block at the TN CD44 -CD25 ϩ stage and to generate double-positive (DP) thymocytes (8) . A 33 kDa glycoprotein, termed pre-Tα, has been found associated with the TCRβ chain in the absence of TCRα on immature thymocytes (9) . Expression of pre-Tα is necessary for the generation of the majority of CD4 ϩ CD8 ϩ αβ-lineage T cells from pre-T cells but is not required for TCRγδ T cell development, and combined with TCRβ and CD3 molecules comprises the pre-TCR complex (10) . The natural ligand for the pre-TCR is unknown. The exact nature of the signal delivered via the pre-TCR complex is also unknown but is believed to involve p56 lck since thymocytes in mice deficient only in p56 lck are also blocked at the TN CD44 -CD25 ϩ stage (11) while expression of a constitutively activated p56 lck negates the block at the TN CD44 -CD25 ϩ stage in RAG-2 -/-mice (12) . Injection of anti-CD3 mAb into RAG-2 -/-mice drives CD44 -CD25 ϩ thymocytes into cell cycle and differentiation into DP thymocytes, mimicking the signal sent through the pre-TCR (13) (14) (15) . The CD44 -CD25 ϩ stage is therefore a critical checkpoint in the development of αβ-lineage T cells since successful rearrangement of the TCRβ chain is necessary for the process to continue beyond this stage of thymocyte development. The protein phosphotyrosine phosphatase CD45 is important at two checkpoints in thymocyte development (16) . First, CD45 is required for normal generation of DP thymocytes, which are reduced~2-fold in CD45-deficient mice. Second, the generation of single-positive thymocytes is severely impaired in these mice, in part as a result of the partial block at the TN stage (16) . Moreover, CD45 is important in TCRmediated apoptosis of thymocytes (16) . Despite significant effort, the function of the extracellular domain of CD45 remains unknown. However, CD45 is heavily O-and N-linked glycosylated, and could serve as a platform for carbohydrate-lectin receptor interactions (17) . This hypothesis is strengthened by the developmentally regulated glycosylation of CD45 (17) . CT1 is one such carbohydrate moiety of CD45 which was originally described in vitro on CTL clones (18, 19) . The CT1 determinant is present at the non-reducing termini of O-linked oligosaccharides and is comprised of GalNAcβ1,4[SAα2,3]-galactose (20) . Recently, the N-acetyl-galactosaminyltransferase that is responsible for addition of the GalNAc residue of the CT1 epitope was cloned, making it feasible to analyze the molecular aspects of CT antigen regulation (21) . In vivo, CT1 is expressed by subsets of intestinal intraepithelial lymphocytes and fetal thymocytes (22, 23) . The fraction of CT1-bearing cells in the thymus is maximal in the fetal thymus, whereas only a very small subset of thymocytes bear CT1 in the adult thymus (22) . Flow cytometric and immunohistological analyses also demonstrated that in the fetal thymus CT1 was expressed by CD25 ϩ subcapsular thymocytes (22) . These results suggest that CT1 might be involved in early T lymphocyte differentiation at the same stage when signaling through the pre-TCR complex is essential for continuation of the maturation process. However, further characterization of the precise stage(s) of thymocyte development at which CT1 is expressed and an analysis of the factors controlling CT1 epitope regulation have not been performed. We now show that the CT1 epitope is temporally regulated during early thymocyte development and that signaling through the pre-TCR complex is responsible for down-modulation of the CT1 determinant through regulation of the CT transferase.
Methods

Mice
Male RAG-2 -/-mice, 8-10 weeks old, were obtained from GenPharm (Palo Alto, CA) and C57BL/6J mice were obtained from Jackson Laboratories (Bar Harbor, ME).
mAb
The mAb used for flow cytometric analysis were: anti-CD25-biotin, anti-CD25-phycoerythrin (PE), anti-CD44-PE, anti-CD4-PE and anti-CD8α-biotin, and were obtained from PharMingen (San Diego, CA). Anti-Ly-1-biotin (anti-CD5) was obtained from Becton Dickinson (Sunnyvale, CA). Staining by biotinylated antibodies was detected with streptavidinRed670 from Gibco/BRL (Gaithersburg, MD). CT1 mAb was purified from ascites fluid and detected using FITC-labeled goat anti-mouse Ig (Cappel, Malvern, PA). Peanut agglutinin (PNA)-FITC was obtained from Sigma (St Louis, MO). For anti-CD3 mAb treatment in vivo, 300 µg of purified 145-2C11 [anti-CD3ε (24)] was injected i.p. into RAG-2 -/-mice.
Immunofluorescence analysis
Single-cell suspensions of thymocytes were produced with a tissue homogenizer and connective tissue removed by passage of the suspension through Nytex. For multi-color flow cytometric analysis, 1ϫ10 6 lymphocytes were transferred into each sample tube, then washed twice with PBS-BSA (PBS ϩ 0.2% BSA ϩ 0.1% NaN 3 ). Lymphocytes were then incubated with both directly conjugated and biotinylated mAb for 20 min at 4°C. The samples were then washed twice with PBS-BSA and then incubated for an additional 20 min at 4°C with streptavidin-Red670. Samples were again washed twice with PBS-BSA and resuspended in 0.5 ml PBS-BSA. The samples were then analyzed on a FACScan (Becton Dickinson). Analysis of flow cytometric data was performed using CellQuest software (Becton Dickinson).
RT-PCR
RNA was isolated from thymocytes using TRIzol (Gibco/BRL, Gaithersburg, MD). One microgram of RNA was subjected to RT using CT transferase primers derived from the published sequence (21) . One-tenth of the RT reaction was subjected to PCR. The resulting products were separated on a 1% agarose gel and detected by ethidium bromide staining. The 3Ј primer sequence was ATCATCATCAAGATCTCGCCGCTA-ATCTGTTTATTGCG and the 5Ј primer sequence was ATCAT-CATCAAGATCTGTTGTGCTGGAGCGAGCTGCGATG. This primer combination yields a fragment of 1600 bp. This fragment was amplified from mouse intestinal epithelial cell RNA and used as a probe in Southern hybridization. Control HPRT mRNA was converted to cDNA, and amplified using primers with the sequences: 5Ј primer GTAATGATCAGTCAACGGGG-GAC and 3Ј primer CCAGCAAGCTTGCAACTTAACCA. This primer combination yields a fragment of 300 bp which was amplified and isolated from thymocyte RNA and used as probe for Southern hybridization. For hybridization, PCR samples were separated on a 1% agarose gel followed by denaturation and transfer to nitrocellulose. Hybridization was carried out at 65°C in 6ϫSSC/5ϫDenhardt's solution containing α 32 -P-labeled probe at a concentration of 10 6 c.p.m./ ml. After washing, the nitrocellulose was exposed to Kodak XAR film.
Results and discussion
CT1, a carbohydrate epitope of CD45, has been shown previously to be expressed on a considerable percentage of fetal but not adult thymocytes, suggesting that CT1 may play a role in early thymocyte development. The earliest of immature progenitors in the thymus are present in small numbers in the adult thymus and can only be examined closely by flow cytometry after the removal of thymocytes at more mature stages. This was accomplished by incubating thymocytes with a biotinylated cocktail of antibodies specific Fig. 1 . The CT1 determinant is expressed by immature thymocyte subsets in normal and RAG-2 -/-mice. (A) Expression of CT1 was analyzed on thymocytes from young adult B6 mice. Thymocytes were isolated and stained with a T-lineage-specific mAb cocktail and mAb to CT1 and CD25. Thymocytes were gated based on expression of T-lineage determinants into T-lin ϩ and T-lin -populations, and analyzed for CT1 epitope and CD25 expression by three-color fluorescence flow cytometry as indicated. As a control, cells were reacted with only the secondary goat anti-mouse Ig-FITC (GAMIGG) used to detect CT1 expression. (B) Expression of the CT1 determinant on RAG-2 -/-thymocytes. Thymocytes were isolated from neonatal (NB) and adult RAG-2 -/-mice and analyzed for expression of the CT1 epitope, CD25, and CD44. The horizontal bars over the histograms demarcate positive staining based on reactivity with only the secondary goat anti-mouse Ig-FITC (GAMIGG) used to detect CT1 expression. The regions shown in the dot plots (R1-R3) correspond to the cell populations analyzed in the histograms for CT1 expression.
for T-lineage antigens (CD3, CD4 and CD8) followed by incubation with streptavidin-Red670. Thymocytes can then be separated into two populations, the more numerous (and more mature) T-lineage ϩ (T-lin ϩ ) cells and the immature progenitors that comprise the T-lineage -population. A comparison of T-lin ϩ and T-lin -thymocytes demonstrated that Tlin ϩ lymphocytes lacked CD25 while a sizeable portion of Tlin -thymocytes were CD25 ϩ (30%) (Fig. 1A) . One-half of the T-lin -thymocytes bearing CD25 in the adult thymus also expressed CT1. Expression of CT1 was therefore not restricted to the fetal period of thymocyte development.
In order to further delineate the subset(s) of cells which express CT1 we examined thymocytes from RAG-2 -/-mice which are blocked at the TN CD44 -CD25 ϩ stage (5). Examination of thymocytes from both newborn and adult RAG-2 -/-mice confirmed that most of the thymocytes were CD44 -CD25 ϩ (a portion are CD44 lo ), and negative for CD4 and CD8 (Fig. 2, uninjected control) . In general, newborn RAG-2 -/-thymocytes are larger than their adult counterparts (data not shown) and perhaps as a result appear to express slightly higher levels of CD25. CD44 ϩ CD25 -(R1), CD44 ϩ CD25 ϩ (R2) and CD44 -CD25 ϩ (R3) thymocyte subsets from newborn and adult RAG-2 -/-mice were analyzed for CT1 expression (Fig. 1B) . A small population of lineage ϩ CD44 int CD25 -cells Fig. 2 . Signaling through CD3 triggers loss of CT1 determinant expression. RAG-2 -/-mice were injected with 300 µg of anti-CD3 mAb i.p. and thymocytes were isolated at 1 and 4 days after injection and analyzed for expression of the CT1 epitope, and either CD25, CD8 or CD5 or for CD4 and CD8 expression by fluorescence flow cytometry. For comparison, thymocytes from uninjected RAG-2 -/-mice were also examined and are shown as Day 0.
was detected and was more prominent in the newborn thymus (Fig. 1B and data not shown) . Since the samples were analyzed by three-color cytometry for CT1, CD44 and CD25 expression we excluded this subset from the analysis by restricting the size of region 1. CD44 ϩ CD25 -cells (R1) in both cases largely lacked the CT1 determinant with low expression on a small percentage of the population. In contrast, the majority of CD44 ϩ CD25 ϩ (R2) cells in both populations expressed high levels of CT1. Fewer adult thymocytes of this subset expressed CT1 and at lower levels than the newborn thymocyte CD44 ϩ CD25 ϩ subset in which nearly all cells expressed homogenous levels of the CT1 determinant. The reason for this difference is unknown but it is possible that the CD25 ϩ CT1 ϩ cells in young mice are progenitors of the CD25 ϩ CT1 -/low cells found later in life. Thus, in the adult thymus, CT1 expression divided the TN CD44 ϩ CD25 ϩ stage, which has not been previously possible by phenotype. Similarly, the adult thymocyte CD44 -CD25 ϩ stage was also divided by expression of CT1 (Fig. 1B, R3 ) and, as has been previously shown, by expression of the BP-3/BST-1 determinant (25) . Unlike the adult population, nearly all neonatal RAG-2 -/-CD44 -CD25 ϩ thymocytes expressed relatively high levels of CT1. These results suggested that the CT1 antigen was up-regulated at the T-committed stage of thymocyte development and expression was maintained until the early pre-T stage. Whether there is a functional distinction between CT1 ϩ and CT1 -late pro-and early pre-T cells will require further analysis. Loss of CT1 expression during maturation could be the result of cell division and/or loss of CT1 ϩ cells through apoptosis or could be the result of active regulation of necessary glycosyltransferases. To test the latter possibility we used a system in which thymocyte differentiation can be induced in vivo. In this system, injection of anti-CD3ε-specific mAb into RAG-2 -/-mice induces differentiation from the TN CD44 -CD25 ϩ stage to the DP stage within 4 days (15). Thus, RAG-2 -/-mice were injected with anti-CD3 mAb to determine whether signaling through the pre-TCR complex would alter CT1 expression. Examination of the thymus from RAG-2 -/-mice injected with anti-CD3 mAb revealed that 24 h postinjection the majority of thymocytes had down-regulated CT1 expression (Fig. 2) . Indeed, around one-third of the cells at this time point had lost CD25 and CT1 expression, while the remainder had begun to down-regulate CT1 and CD25 expression. The CD25 -cells also lacked CD44 and thus were phenotypically identical to late pre-T cells. At this time point cell numbers had increased at most 1.5-fold (from 4.5ϫ10 6 to 7ϫ10 6 on average), suggesting that loss and/or substantial division of cells was unlikely to be entirely responsible for the observed effects. At 24 h after anti-CD3 mAb injection CD4 and CD8 were not expressed but CD5 expression had increased dramatically with 67% of the cells bearing CD5. Prior to injection of anti-CD3 mAb, thymocytes in RAG-2 -/-mice expressed very little CD5 (Fig. 2) . Four days postinjection of anti-CD3 mAb nearly all the cells had lost CD25 expression while a small population expressed low levels of the CT1 determinant. Most cells were CD5 high and many were CD4 ϩ CD8 ϩ . Those cells expressing CT1 lacked CD4 and CD8 as was the case in normal adult thymus. Seven days after anti-CD3 mAb injection few cells expressed the CT1 determinant (data not shown). These findings demonstrated that ligation of CD3 at the early pre-T cell stage induced the loss of the CT1 epitope, suggesting that TCRβ selection during normal thymocyte development was responsible for CT determinant down-regulation.
In order to determine at what level CT determinant addition was being controlled we analyzed CT transferase mRNA levels in thymocytes before and after anti-CD3 mAb treatment. The cDNA encoding the glycosyltransferase responsible for addition of the GalNAc of the CT1 epitope has recently been Fig. 3 . Down-modulation of CT transferase mRNA is induced by CD3 triggering. RT-PCR was performed using RNA from RAG-2 -/-mice injected with anti-CD3 mAb. PCR amplification with specific primers followed by Southern hybridization was used to detect CT transferase mRNA (1.6 kb) or HPRT mRNA (0.3 kb). Lane 1, uninjected RAG-2 -/-thymocytes; lane 2, RAG-2 -/-thymocytes 1 day after anti-CD3 mAb treatment; lane 3, RAG-2 -/-thymocytes 4 days after anti-CD3 mAb treatment; lane 4, DP thymocytes from adult B6 mice.
cloned and sequenced (21) . Transfection of the CT transferase cDNA into CHO cells resulted in expression of the CT1 determinant at the cell surface. mRNA for CT transferase is expressed in a number of different cell types, including epithelial cells and intraepithelial lymphocytes of the small intestine (21 and data not shown). When we analyzed RAG-2 -/-thymocyte RNA by RT-PCR, CT transferase mRNA was easily detectable (Fig. 3, lane 1) . In contrast, 1 and 4 days after anti-CD3 mAb injection, a major reduction in CT transferase mRNA was observed (Fig. 3, lanes 2 and 3) . No difference was observed in the amount of control HPRT mRNA detected (Fig. 3) . Since cell numbers did not change in the 24 h after anti-CD3 mAb injection and only limited proliferation would be expected in this time period, this data demonstrated that the down-modulation of the CT-determinant by CD3 ligation was due, for the most part, to loss of CT transferase mRNA. This effect could be due to down-regulation of transcription and/or changes in mRNA degradation. In addition, CD45 turnover could also be affected by anti-CD3 mAb treatment, thereby increasing the rapidity of CT1 epitope loss. The remaining CT transferase mRNA that is detected after CD3 triggering was presumably derived from the small population of remaining CT1 low thymocytes.
To test whether CD3 ligation in immature thymocytes induced alterations in glycosylation concomitant with loss of the CT1 epitope, we analyzed expression of receptors for the lectin, PNA. PNA was chosen since expression of the carbohydrate ligand for PNA is highest at the DP stage of thymocyte maturation (26) and immature progenitors at the TN stage for the most part lack PNA ligands. In addition, CD45 is one of the proteins which carries PNA-specific glycans (27) . Examination of thymocytes from RAG-2 -/-thymocytes confirmed that most TN thymocytes did not bind PNA, although about one-third bound intermediate amounts of PNA (Fig. 4) . Interestingly, injection of anti-CD3 mAb triggered upregulation of PNA ligand, which was detectable as early as 24 h post-injection (data not shown). By 4 days after anti-CD3 mAb injection,~70% of the cells expressed high levels of PNA ligand (Fig. 4) . The increase in PNA binding occurred concomitantly with the loss of the CT1 determinant (Fig. 4B) . The down-regulation of one carbohydrate epitope (CT1) coupled with the up-regulation of another (PNA) suggested that carbohydrates play a complex role in thymocyte maturation.
The injection of anti-CD3 mAb into RAG-2 -/-mice is thought to induce a signal which mimics the signal sent through the pre-TCR complex at the TN CD44 -CD25 ϩ stage that enables the thymocyte to complete the maturation process. Downregulation of CT1 at this stage implies that expression of the CT1 epitope is necessary at the pro/pre-T stages of thymocyte development but that continued expression of the CT1 epitope is not required, and more significantly, might be harmful or inhibitory if expressed at later stages in the maturation process. Thus, determining the molecular parameters of CT1 determinant control by the pre-TCR is of potential significance to T cell development in general.
The expression of CT1 at a specific checkpoint in T cell development begs the question of why such tightly controlled regulation of a carbohydrate is necessary during thymocyte differentiation. Yet, there are many precedents for developmental glycan regulation in T cells. For example, 9-Oacetylated sialomucin is expressed by more mature CD4 ϩ CD8 -thymocytes but not by DP cells and is downmodulated following activation (28) . There is also potential for carbohydrate ligand-receptor interactions in the thymus. Mounting evidence supports the concept that CD45 carries developmentally important carbohydrate structures which react with receptors expressed by thymic stromal and accessory cells. Thus, the C-type lectin serum mannan binding protein reacts specifically with a uniquely glycosylated form of CD45 that is expressed by immature mouse DP thymocytes but not by mature T cells (29) . Furthermore, galectin-1, a β-galactoside binding protein expressed by thymic stromal cells, may be involved in induction of apoptosis during thymocyte development (30) . The galectin-1-T cell interaction is dependent on the expression of CD45-specific glycans (31) , underscoring the potential importance of CD45 interactions with lectin-like receptors during T cell development. In mice lacking CD45 completely, differentiation from the double-negative to DP stage is impaired (16) indicating that CD45 may play a role in pre-TCR signaling, perhaps via interaction with p56 lck (32) . Thus, the CT1 epitope might be seen as regulating the interaction between the developing thymocyte and the thymic stroma at a specific point in development. Alternatively, the CT1 determinant may have a role in thymocyte turnover. Thymocytes at the CD44 -CD25 ϩ stage undergo a high rate of turnover such that 70% or more of the thymocytes that reach the CD44 -CD25 ϩ stage are destined to die (33) . Thus, interaction of a stromal receptor with the CT1 epitope could enhance, or perhaps inhibit, apoptosis at the pre-TCR selection step. Genetic manipulation of the genes encoding developmentally regulated glycosyltransferases should provide clues to the function of CD45-associated carbohydrate determinants.
